Диссертация (1145852), страница 16
Текст из файла (страница 16)
Т. 166. № 2. — C. 285-90.82. Kang M.H., Singaraja R., Hayden M.R. Adenosine-triphosphate-bindingcassette transporter-1 trafficking and function // Trends Cardiovasc Med. 2010. Т. 20. №2. — C. 41-9.83. Kaplan R., Gan X., Menke J.G., Wright S.D., Cai T.Q. Bacteriallipopolysaccharide induces expression of ABCA1 but not ABCG1 via an LXRindependent pathway // J Lipid Res. 2002. Т.
43. № 6. — C. 952-9.84. Kappus M.S., Murphy A.J., Abramowicz S., Ntonga V., Welch C.L., TallA.R., Westerterp M. Activation of liver X receptor decreases atherosclerosis in Ldlr(-)/() mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells //Arterioscler Thromb Vasc Biol. 2014. Т. 34. № 2. — C. 279-84.85. Karasinska J.M., Rinninger F., Lutjohann D., Ruddle P., Franciosi S., KruitJ.K., Singaraja R.R., Hirsch-Reinshagen V., Fan J., Brunham L.R., Bissada N.,Ramakrishnan R., Wellington C.L., Parks J.S., Hayden M.R. Specific loss of brainABCA1 increases brain cholesterol uptake and influences neuronal structure and function// J Neurosci. 2009.
Т. 29. № 11. — C. 3579-89.86. Kennedy M.A., Barrera G.C., Nakamura K., Baldan A., Tarr P., FishbeinM.C., Frank J., Francone O.L., Edwards P.A. ABCG1 has a critical role in mediatingcholesterol efflux to HDL and preventing cellular lipid accumulation // Cell Metab. 2005.Т. 1. № 2. — C. 121-31.87. Khera A.V., Cuchel M., de la Llera-Moya M., Rodrigues A., Burke M.F.,Jafri K., French B.C., Phillips J.A., Mucksavage M.L., Wilensky R.L., Mohler E.R.,104Rothblat G.H., Rader D.J. Cholesterol efflux capacity, high-density lipoprotein function,and atherosclerosis // N Engl J Med. 2011.
Т. 364. № 2. — C. 127-35.88. Khokha R., Murthy A., Weiss A. Metalloproteinases and their naturalinhibitors in inflammation and immunity // Nat Rev Immunol. 2013. Т. 13. № 9. — C.649-65.89. Kiss M., Czimmerer Z., Nagy L. The role of lipid-activated nuclear receptorsin shaping macrophage and dendritic cell function: From physiology to pathology // JAllergy Clin Immunol. 2013. Т.
132. № 2. — C. 264-86.90. Laemmli U.K. Cleavage of structural proteins during the assembly of thehead of bacteriophage T4 // Nature. 1970. Т. 227. № 5259. — C. 680-5.91. Laffitte B.A., Joseph S.B., Walczak R., Pei L., Wilpitz D.C., Collins J.L.,Tontonoz P.
Autoregulation of the human liver X receptor alpha promoter // Mol CellBiol. 2001. Т. 21. № 22. — C. 7558-68.92. Lahiri D.K., Bye S., Nurnberger JI.Jr., Hodes M.E., Crisp M. A non-organicand non-enzymatic extraction method gives higher yields of genomic DNA from wholeblood samples than do nine other methods tested // J.
Biochem. Biophys. Methods. 1992.Т.25, № 4. – C.193-20593. Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.F., Chimini G.,Kaminski W.E., Schmitz G. Molecular cloning of the human ATP-binding cassettetransporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages //Biochem Biophys Res Commun. 1999.
Т. 257. № 1. — C. 29-33.94. Levitan I., Volkov S., Subbaiah P.V. Oxidized LDL: diversity, patterns ofrecognition, and pathophysiology // Antioxid Redox Signal. 2010. Т. 13. № 1. — C. 3975.95. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W.,Valledor A.F., Davis R.A., Willson T.M., Witztum J.L., Palinski W., Glass C.K.Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice byPPARalpha, beta/delta, and gamma // J Clin Invest. 2004.
Т. 114. № 11. — C. 1564-76.96. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K.Peroxisome proliferator-activated receptor gamma ligands inhibit development of105atherosclerosis in LDL receptor-deficient mice // J Clin Invest. 2000. Т. 106. № 4. — C.523-31.97.
Li G., Biju K.C., Xu X., Zhou Q., Chen C., Valente A.J., He W., ReddickR.L., Freeman G.L., Ahuja S.S., Clark R.A., Li S. Macrophage LXRalpha gene therapyameliorates atherosclerosis as well as hypertriglyceridemia in LDLR(-/-) mice // GeneTher. 2011. Т. 18. № 8. — C. 835-41.98. Liu H.F., Cui K.F., Wang J.P., Zhang M., Guo Y.P., Li X.Y., Jiang C.Significance of ABCA1 in human carotid atherosclerotic plaques // Exp Ther Med.
2012.Т. 4. № 2. — C. 297-302.99. Liu L., Guo Z.G., Wang Q.G., Liu S.L., Lai W.Y., Tu Y. Significance of 191G/C polymorphisms in the promoter region of ATP-binding cassette transporter genein coronary artery disease // Di Yi Jun Yi Da Xue Bao 2005. Т.25. №6. — С. 660-666.100. Liu Y., Tang C. Regulation of ABCA1 functions by signaling pathways //Biochim Biophys Acta. 2012.
Т. 1821. № 3. — C. 522-9.101. Lo Sasso G., Murzilli S., Salvatore L., D'Errico I., Petruzzelli M., Conca P.,Jiang Z.Y., Calabresi L., Parini P., Moschetta A. Intestinal specific LXR activationstimulates reverse cholesterol transport and protects from atherosclerosis // Cell Metab.2010. Т. 12. № 2. — C. 187-93.102. Lopez-Otin C., Palavalli L.H., Samuels Y. Protective roles of matrixmetalloproteinases: from mouse models to human cancer // Cell Cycle. 2009. Т.
8. № 22.— C. 3657-62.103. Lundberg A.M., Hansson G.K. Innate immune signals in atherosclerosis //Clin Immunol. 2010. Т. 134. № 1. — C. 5-24.104. Lutucuta S., Ballantyne C.M., Elghannam H., Gotto A.M., Jr., Marian A.J.Novel polymorphisms in promoter region of atp binding cassette transporter gene andplasma lipids, severity, progression, and regression of coronary atherosclerosis andresponse to therapy // Circ Res. 2001.
Т. 88. № 9. — C. 969-73.106105. Ma L., Dong F., Zaid M., Kumar A., Zha X. ABCA1 protein enhances Tolllike receptor 4 (TLR4)-stimulated interleukin-10 (IL-10) secretion through protein kinaseA (PKA) activation // J Biol Chem. 2012. Т. 287. № 48. — C. 40502-12.106. Ma X.Y., Liu J.P., Song Z.Y. Associations of the ATP-binding cassettetransporter A1 R219K polymorphism with HDL-C level and coronary artery disease risk:a meta-analysis // Atherosclerosis. 2011. Т.
215. № 2. — C. 428-34.107. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., UmesonoK., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptorsuperfamily: the second decade // Cell. 1995. Т. 83. № 6. — C. 835-9.108. Marenberg M.E., Risch N., Berkman L.F., Floderus B., de Faire U. Geneticsusceptibility to death from coronary heart disease in a study of twins // N Engl J Med.1994.
Т. 330. № 15. — C. 1041-6.109. Martinez L.O., Agerholm-Larsen B., Wang N., Chen W., Tall A.R.Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and isreversed by ApoA-I // J Biol Chem. 2003. Т. 278. № 39. — C. 37368-74.110. McLaren J.E., Michael D.R., Ashlin T.G., Ramji D.P.
Cytokines,macrophage lipid metabolism and foam cells: implications for cardiovascular diseasetherapy // Prog Lipid Res. 2011. Т. 50. № 4. — C. 331-47.111. Meurs I., Van Eck M., Van Berkel T.J. High-density lipoprotein: keymolecule in cholesterol efflux and the prevention of atherosclerosis // Curr Pharm Des.2010.
Т. 16. № 13. — C. 1445-67.112. Michael D.R., Ashlin T.G., Buckley M.L., Ramji D.P. Liver X receptors,atherosclerosis and inflammation // Curr Atheroscler Rep. 2012. Т. 14. № 3. — C. 28493.113. Miller G.J., Miller N.E. Plasma-high-density-lipoprotein concentration anddevelopment of ischaemic heart-disease // Lancet. 1975. Т. 1. № 7897. — C. 16-9.114. Miller M., Rhyne J., Hong S.H., Friel G., Dolinar C., Riley W. Do mutationscausing low HDL-C promote increased carotid intima-media thickness? // Clin ChimActa.
2007. Т. 377. № 1-2. — C. 273-5.107115. Mishra P.K., Givvimani S., Chavali V., Tyagi S.C. Cardiac matrix: a clue forfuture therapy // Biochim Biophys Acta. 2013. Т. 1832. № 12. — C. 2271-6.116. Mitra S., Goyal T., Mehta J.L. Oxidized LDL, LOX-1 and atherosclerosis //Cardiovasc Drugs Ther. 2011. Т. 25. № 5. — C. 419-29 - b.117. Morishige K., Shimokawa H., Matsumoto Y., Eto Y., Uwatoku T., Abe K.,Sueishi K., Takeshita A. Overexpression of matrix metalloproteinase-9 promotesintravascular thrombus formation in porcine coronary arteries in vivo // Cardiovasc Res.2003. Т. 57.
№ 2. — C. 572-85.118. Nabel E.G. Cardiovascular disease // N Engl J Med. 2003. Т. 349. № 1. —C. 60-72.119. Nagy Z.S., Czimmerer Z., Nagy L. Nuclear receptor mediated mechanismsof macrophage cholesterol metabolism // Mol Cell Endocrinol. 2013. Т. 368. № 1-2. —C. 85-98.120. Naik S.U., Wang X., Da Silva J.S., Jaye M., Macphee C.H., Reilly M.P.,Billheimer J.T., Rothblat G.H., Rader D.J. Pharmacological activation of liver Xreceptors promotes reverse cholesterol transport in vivo // Circulation. 2006. Т. 113. №1.
— C. 90-7.121. National Cholesterol Education Program Expert Panel on Detection E.,Treatment of High Blood Cholesterol in A. Third Report of the National CholesterolEducation Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults (Adult Treatment Panel III) final report // Circulation.2002. Т. 106.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
